JP2021534116A5 - - Google Patents
Info
- Publication number
- JP2021534116A5 JP2021534116A5 JP2021506718A JP2021506718A JP2021534116A5 JP 2021534116 A5 JP2021534116 A5 JP 2021534116A5 JP 2021506718 A JP2021506718 A JP 2021506718A JP 2021506718 A JP2021506718 A JP 2021506718A JP 2021534116 A5 JP2021534116 A5 JP 2021534116A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- use according
- heteroaryl
- alkenyl
- aralkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862718926P | 2018-08-14 | 2018-08-14 | |
| US62/718,926 | 2018-08-14 | ||
| US201962836507P | 2019-04-19 | 2019-04-19 | |
| US62/836,507 | 2019-04-19 | ||
| PCT/US2019/046408 WO2020036997A1 (en) | 2018-08-14 | 2019-08-13 | Treatment of relapsed follicular lymphoma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021534116A JP2021534116A (ja) | 2021-12-09 |
| JP2021534116A5 true JP2021534116A5 (https=) | 2022-08-19 |
Family
ID=69525835
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021506718A Pending JP2021534116A (ja) | 2018-08-14 | 2019-08-13 | 再発性の濾胞性リンパ腫の処置 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20210196725A1 (https=) |
| EP (1) | EP3836936A4 (https=) |
| JP (1) | JP2021534116A (https=) |
| KR (1) | KR20210043637A (https=) |
| CN (1) | CN112839659A (https=) |
| AU (1) | AU2019321526A1 (https=) |
| BR (1) | BR112021002734A2 (https=) |
| CA (1) | CA3109377A1 (https=) |
| IL (1) | IL280721A (https=) |
| MA (1) | MA53237A (https=) |
| MX (1) | MX2021001765A (https=) |
| SG (1) | SG11202101417XA (https=) |
| TW (1) | TW202021593A (https=) |
| WO (1) | WO2020036997A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI572599B (zh) | 2011-03-28 | 2017-03-01 | Ｍｅｉ製藥公司 | （α－經取代之芳烷胺基及雜芳烷胺基）嘧啶基及１，３，５－三基苯并咪唑，其醫藥組合物及其在治療增生性疾病之用途 |
| US11304953B2 (en) | 2017-05-23 | 2022-04-19 | Mei Pharma, Inc. | Combination therapy |
| KR20200041358A (ko) | 2017-08-14 | 2020-04-21 | 메이 파마, 아이엔씨. | 병용 요법 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2919869B1 (fr) * | 2007-08-09 | 2009-09-25 | Sanofi Aventis Sa | Nouveaux derives de n, n'-2,4-dianilinopyrimidines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk |
| TWI572599B (zh) * | 2011-03-28 | 2017-03-01 | Ｍｅｉ製藥公司 | （α－經取代之芳烷胺基及雜芳烷胺基）嘧啶基及１，３，５－三基苯并咪唑，其醫藥組合物及其在治療增生性疾病之用途 |
| AU2013299627C1 (en) * | 2012-08-09 | 2018-05-31 | Celgene Corporation | Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione |
| MA38462A1 (fr) * | 2013-04-08 | 2017-10-31 | Bayer Pharma AG | Utilisation de 2,3-dihydroimidazo[1,2-c]quinazolines substituées pour le traitement de lymphomes |
| HUE049175T2 (hu) * | 2014-09-23 | 2020-09-28 | Hoffmann La Roche | Eljárás anti-CD79b immunkonjugátumok alkalmazására |
| IL292938A (en) * | 2016-09-19 | 2022-07-01 | Mei Pharma Inc | Combined treatment |
| KR20200041358A (ko) * | 2017-08-14 | 2020-04-21 | 메이 파마, 아이엔씨. | 병용 요법 |
-
2019
- 2019-08-13 BR BR112021002734-3A patent/BR112021002734A2/pt not_active IP Right Cessation
- 2019-08-13 EP EP19849643.2A patent/EP3836936A4/en not_active Withdrawn
- 2019-08-13 WO PCT/US2019/046408 patent/WO2020036997A1/en not_active Ceased
- 2019-08-13 SG SG11202101417XA patent/SG11202101417XA/en unknown
- 2019-08-13 CN CN201980067638.8A patent/CN112839659A/zh active Pending
- 2019-08-13 AU AU2019321526A patent/AU2019321526A1/en not_active Abandoned
- 2019-08-13 MX MX2021001765A patent/MX2021001765A/es unknown
- 2019-08-13 JP JP2021506718A patent/JP2021534116A/ja active Pending
- 2019-08-13 KR KR1020217007422A patent/KR20210043637A/ko not_active Ceased
- 2019-08-13 CA CA3109377A patent/CA3109377A1/en active Pending
- 2019-08-13 US US17/268,050 patent/US20210196725A1/en not_active Abandoned
- 2019-08-13 MA MA053237A patent/MA53237A/fr unknown
- 2019-08-14 TW TW108128971A patent/TW202021593A/zh unknown
-
2021
- 2021-02-08 IL IL280721A patent/IL280721A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6434482B2 (ja) | 置換アシルアニリドおよびそれらの使用方法 | |
| JP2022520061A5 (https=) | ||
| JP2021534116A5 (https=) | ||
| JP2015536986A5 (https=) | ||
| JP2014500870A5 (https=) | ||
| JP2024156774A5 (https=) | ||
| CN102497864B (zh) | 用于预防或治疗由化疗诱发的疼痛的σ配体 | |
| JP2020528889A5 (https=) | ||
| JP2014528464A5 (https=) | ||
| JP2018523689A5 (https=) | ||
| JP2013501731A5 (https=) | ||
| JP2018514544A5 (https=) | ||
| JP2020507589A5 (https=) | ||
| RU2015121424A (ru) | Комбинированная терапия | |
| JP2022550919A5 (https=) | ||
| US9889110B2 (en) | Selective androgen receptor modulator for treating hormone-related conditions | |
| JP2010503620A5 (https=) | ||
| JP2019529460A5 (https=) | ||
| JP2022508513A5 (https=) | ||
| JP2016516792A (ja) | α−２アドレノレセプターおよびシグマレセプターリガンドの組み合わせ物 | |
| US20150065526A1 (en) | Overcoming acquired resistance to chemotherapy treatments through suppression of stat3 | |
| JP2021534115A5 (https=) | ||
| JP2019516726A5 (https=) | ||
| JP2024516430A5 (https=) | ||
| JP2025509278A5 (https=) |